Goldman Sachs
NGEN

Goldman Sachs’s NervGen Pharma NGEN Stock Holding History

Goldman Sachs’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.4K Buy
+19,623
New +$60.9K ﹤0.01% 6433

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Goldman Sachs's NGEN Position: Q2 2026 in Review

Goldman Sachs opened a new position in NervGen Pharma (NGEN) in Q2 2026: 19,623 shares worth $40.4K. The stake represents ﹤0.01% of the portfolio and ranks #6433 among its holdings.

62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Goldman Sachs held 19,623 shares of NervGen Pharma worth $40.4K as of Q2 2026.
  • NervGen Pharma was a new Goldman Sachs position in Q2 2026.
  • NervGen Pharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6433 holding.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.